

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>IN01630</b>		SERIAL NO.: <b>10/667,856</b>	
<b>INFORMATION DISCLOSURE STATEMENT FOR PATENT</b> (Use several sheets if necessary)				APPLICANT: <b>Courtney and Laughlin</b>			
				FILING DATE: <b>September 22, 2003</b>		GROUP: <b>1617</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
KS	AA	Ezzet <i>et al.</i> , "The pharmacokinetics of posaconazole in neutropenic oncology patients," <i>Abstract from the 41<sup>st</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Illinois, USA; September 22-25, 2001, 41:4 (2001).</i>					
KS	AB	Mellinghoff <i>et al.</i> , "Use of posaconazole (SCH56592) for treatment of invasive fungal infections refractory to standard antifungal therapy" (Abstract from the 42 <sup>nd</sup> Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000), <i>Blood, 96(11 Part 2):341b (2000).</i>					
KS	AC	Skiest <i>et al.</i> , "Treatment of azole-refractory candidiasis in HIV disease," <i>Abstract from the 39<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, California, USA; September 26-29, 1999, 39:489 (1999).</i>					
KS	AD	Petratiene <i>et al.</i> , "Correlation between serum galactomannan concentrations and antifungal efficacy of posaconazole (SCH 56592) in treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits," <i>Abstract from the 40<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000, 40:380-381 (2000).</i>					
KS	AE	Connolly <i>et al.</i> , "Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice," <i>Antimicrobial Agents and Chemotherapy, 44(10):2604-2608 (2000).</i>					
EXAMINER		DATE CONSIDERED					
Kantamuri Sd/22		12/12/06					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							